Logo image of ZLNA.OL

ZELLUNA ASA (ZLNA.OL) Stock Fundamental Analysis

OSL:ZLNA - NO0013524942 - Common Stock

13.5 NOK
0 (-0.01%)
Last: 9/3/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ZLNA scores 2 out of 10 in our fundamental rating. ZLNA was compared to 74 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZLNA as it has an excellent financial health rating, but there are worries on the profitability. ZLNA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ZLNA has reported negative net income.
ZLNA had a negative operating cash flow in the past year.
ZLNA had negative earnings in each of the past 5 years.
ZLNA had a negative operating cash flow in each of the past 5 years.
ZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -170.55%, ZLNA is doing worse than 85.14% of the companies in the same industry.
ZLNA has a Return On Equity of -213.94%. This is in the lower half of the industry: ZLNA underperforms 63.51% of its industry peers.
Industry RankSector Rank
ROA -170.55%
ROE -213.94%
ROIC N/A
ROA(3y)-86.89%
ROA(5y)-61.71%
ROE(3y)-116.09%
ROE(5y)-80.15%
ROIC(3y)N/A
ROIC(5y)N/A
ZLNA.OL Yearly ROA, ROE, ROICZLNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ZLNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZLNA.OL Yearly Profit, Operating, Gross MarginsZLNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ZLNA remains at a similar level compared to 1 year ago.
The number of shares outstanding for ZLNA has been increased compared to 5 years ago.
Compared to 1 year ago, ZLNA has a worse debt to assets ratio.
ZLNA.OL Yearly Shares OutstandingZLNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ZLNA.OL Yearly Total Debt VS Total AssetsZLNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.17 indicates that ZLNA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.17, ZLNA is in the better half of the industry, outperforming 77.03% of the companies in the same industry.
ZLNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.17
ROIC/WACCN/A
WACCN/A
ZLNA.OL Yearly LT Debt VS Equity VS FCFZLNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.95 indicates that ZLNA has no problem at all paying its short term obligations.
ZLNA has a Current ratio of 3.95. This is in the better half of the industry: ZLNA outperforms 75.68% of its industry peers.
A Quick Ratio of 3.95 indicates that ZLNA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.95, ZLNA is in the better half of the industry, outperforming 75.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.95
Quick Ratio 3.95
ZLNA.OL Yearly Current Assets VS Current LiabilitesZLNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.94% over the past year.
EPS 1Y (TTM)14.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 34.81% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.02%
EPS Next 2Y34.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZLNA.OL Yearly Revenue VS EstimatesZLNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2M 4M 6M 8M
ZLNA.OL Yearly EPS VS EstimatesZLNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZLNA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZLNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZLNA.OL Price Earnings VS Forward Price EarningsZLNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLNA.OL Per share dataZLNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

ZLNA's earnings are expected to grow with 34.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.81%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZLNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZELLUNA ASA

OSL:ZLNA (9/3/2025, 7:00:00 PM)

13.5

0 (-0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-20 2025-08-20
Earnings (Next)11-06 2025-11-06
Inst Owners16.41%
Inst Owner ChangeN/A
Ins Owners1.15%
Ins Owner ChangeN/A
Market Cap276.07M
Analysts42.22
Price Target25.5 (88.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-56.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 55215
P/FCF N/A
P/OCF N/A
P/B 2.96
P/tB 3.64
EV/EBITDA N/A
EPS(TTM)-44.31
EYN/A
EPS(NY)-7.96
Fwd EYN/A
FCF(TTM)-7.94
FCFYN/A
OCF(TTM)-7.93
OCFYN/A
SpS0
BVpS4.56
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -170.55%
ROE -213.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.89%
ROA(5y)-61.71%
ROE(3y)-116.09%
ROE(5y)-80.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.81%
Cap/Sales 7520%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.95
Quick Ratio 3.95
Altman-Z 3.17
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.96%
Cap/Depr(5y)41.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.89%
EPS Next Y89.02%
EPS Next 2Y34.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.78%
OCF growth 3YN/A
OCF growth 5YN/A